Axial Biotherapeutics Named a “Fierce 15” Biotech Company of 2017 by FierceBiotech

BOSTON and Pasadena, Calif., September 26, 2017 – Axial Biotherapeutics, a biotechnology company building a unique class of microbial-targeted therapeutics for neurological diseases, today announced that it has been named by FierceBiotech as one of 2017’s Fierce 15 biotechnology companies, designating it as a promising and innovative private biotech company whose research and development work has helped to transform the industry.


“It is an honor to be a recipient of this year’s FierceBiotech’s Fierce 15 award,” said David H. Donabedian, Ph.D., CEO and Co-Founder of Axial Biotherapeutics. “The credit goes to our dedicated team and advisors who have been working together to pioneer a new treatment path for neurological diseases and disorders through targeting the gut microbiome as well as building the company over the past year. This important recognition is also a testament to the groundbreaking research of our scientific co-founder Sarkis K. Mazmanian, Ph.D. which is the basis of our lead programs in Autism Spectrum Disorders and Parkinson’s Disease and we are commited to bring this exciting approach into the clinic in the near future.”


The Fierce 15 award celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s fifteenth annual Fierce 15 selection. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.


About FierceBiotech


An internationally recognized daily report reaching a network of more than 275,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day’s top stories. Every business day, FierceBiotech and its family of publications covers the waterfront in drug development, from pre-clinical science to seed funding and venture capital, through IPOs and licensing, clinical testing, regulatory changes, M&A and beyond. Signup is free at www.fiercebiotech.com/signup.


About Axial Therapeutics


Axial Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders. The company is leveraging its expertise in the gut-brain axis and its unique drug development platform to advance novel therapies that have the potential to transform the treatment paradigm in neurological diseases. Axial is advancing a pipeline of small molecule product candidates with lead clinical programs that address underlying pathology and resulting symptoms in Autism Spectrum Disorder (ASD) and Parkinson’s Disease (PD), and additional preclinical initiatives in small molecules in other areas of autism and PD, as well as oncology and rare CNS diseases.


Contacts for Axial Therapeutics


Media:

Mike Beyer
Sam Brown, Inc.
312-961-2502
mikebeyer@sambrown.com


Investors:

Jeffrey Young, CFO
781-701-8467
jeffrey@axialtx.com